articleTop 1% cited
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Journal of Clinical Oncology · 1998 · Vol. 16(8) · pp. 2825–2833
Peter McLaughlin✉(The University of Texas MD Anderson Cancer Center)A.J. Grillo-LópezBrian K. LinkRonald LevyM. S. CzuczmanMichael E. WilliamsMeyer R. HeymanIsabelle Bence‐BrucklerChristine A. WhiteFernando CabanillasVinay JainAnthony D. HoJohn ListerKen WeyDiying ShenB.K. Dallaire
Abstract
The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy. Toxicity was mild. Attention needs to be paid to the rate of antibody infusion, with titration according to toxicity. Further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchMedicineChillsRituximabLymphomaAntibodyInternal medicineMonoclonal antibodyAdverse effectChemotherapyCD20
MeSH terms
RituximabAdultAgedAntibodies, MonoclonalAntineoplastic AgentsDrug Administration ScheduleFemaleHumansLymphoma, FollicularLymphoma, Non-HodgkinMaleMiddle AgedRecurrenceLymphoma, B-CellDisease Progression
Funding
- IC Design Education Center
Citations
2,755
FWCI
64.22
field-weighted impact
References
23
Percentile
100%
vs. same field & year
Citations per year
Cited by
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
Blood · 2002 · 1,862 citations
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Frontiers in Oncology · 2018 · 356 citations
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Lara D. Veeken · 2001 · 517 citations
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
Journal of Clinical Oncology · 1999 · 3,285 citations
Rituximab
Drugs · 2003 · 470 citations
Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action
American Journal of Transplantation · 2006 · 611 citations
Protein therapeutics: a summary and pharmacological classification
Nature Reviews Drug Discovery · 2007 · 2,066 citations
References
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Blood · 1994 · 1,936 citations
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
Blood · 1997 · 1,692 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.